1q24-q25

A chromosome band present on 1q
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2011
012320002011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Reports of individuals with deletions of 1q24→q25 share common features of prenatal onset growth deficiency, microcephaly, small… (More)
Is this relevant?
2011
2011
Family, twin and adoption studies have clearly demonstrated that genetic factors are important in modulating the vulnerability to… (More)
Is this relevant?
2011
2011
Knuckle pads and camptodactyly are overlapping symptoms associated with many genetic and environmental factors. To the best of… (More)
Is this relevant?
2008
2008
INTRODUCTION Few conventional cytogenetic studies of squamous cell carcinoma (SCC) have been performed to date. The introduction… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2007
2007
We report on a 26-year-old patient presenting with extremely short stature (height 72cm, weight 6.5kg, OFC 42.5cm), facial… (More)
Is this relevant?
2005
2005
OBJECTIVE The vesicle-associated membrane protein-4 (VAMP4) gene is an excellent type 2 diabetes (T2DM) positional candidate gene… (More)
Is this relevant?
2003
2003
After lung cancer, prostate cancer is the second leading cause of death from cancer in men in developed countries. Despite the… (More)
  • table 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The RNASEL gene (2',5'-oligoisoadenylate-synthetase dependent) encodes a ribonuclease that mediates the antiviral and apoptotic… (More)
Is this relevant?
Review
2001
Review
2001
.......................................................................................................................................................... 8 INTRODUCTION ................................................................................................................................................. 9 REVIEW OF THE LITERATURE ................................................................................................................... 10 1. NATURAL HISTORY OF PROSTATE CANCER ..................................................................................................... 10 1.1. Histology and histogenesis of prostate cancer...................................................................................... 10 1.2. Androgen dependency and treatment of prostate cancer ..................................................................... 10 2. EPIDEMIOLOGY OF PROSTATE CANCER ........................................................................................................... 11 2.1. Trends in incidence and mortality of prostate cancer .......................................................................... 11 2.2. PSA screening......................................................................................................................................... 12 2.3. Risk factors for prostate cancer ............................................................................................................ 13 2.4 Hereditary prostate cancer...................................................................................................................... 17 3. GENES PREDISPOSING TO CANCER .................................................................................................................. 22 3.1. Knudson’s hypothesis and cancer-predisposition genes ...................................................................... 22 3.2. Multistep development and progression of cancer ............................................................................... 24 4. GENETIC BASIS OF HEREDITARY PREDISPOSITION TO PROSTATE CANCER ...................................................... 25 4.1 HPC1 locus at 1q24-q25 ......................................................................................................................... 25 4.2 PCAP locus at 1q42-q43 ......................................................................................................................... 26 4.3. HPCX locus at Xq27-q28 ....................................................................................................................... 26 4.4. CAPB locus at 1p36................................................................................................................................ 27 4.5. HPC2/ELAC2 gene locus at 17p ............................................................................................................ 27 4.6. Recent genome-wide linkage scan results and putative HPC loci at 20q13, 16q, and other sites....... 27 4.7. Linkage studies at previously identified loci ......................................................................................... 28 4.8. BRCA1 and BRCA2 genes ...................................................................................................................... 30 4.9. Other candidate prostate cancer susceptibility genes ........................................................................... 30 4.10. Pathology and clinical course of hereditary prostate cancer ............................................................. 32 5. CHALLENGES FOR THE GENETIC DISSECTION OF COMPLEX TRAITS ................................................................. 33 5.1 Factors complicating linkage analysis of prostate cancer .................................................................... 34 5.2 Strategies for complex traits.................................................................................................................... 35 AIMS OF THE STUDY ...................................................................................................................................... 37 MATERIALS AND METHODS........................................................................................................................ 38 1. DATA SOURCES .............................................................................................................................................. 38 2. INDEX PATIENTS AND RELATIVES ................................................................................................................... 38 2.1. Estimation of standardized incidence ratios (Study I).......................................................................... 38 2.2. Cancer registry -based method for cancer family ascertainment (Study II)........................................ 39 2.3. Collection of Finnish hereditary prostate cancer families for linkage studies (Studies III and IV) .. 39 2.4. Association of E-Cadherin germline alterations with prostate and gastric cancers (Study V) ........... 40 2.5. Prostate spesific antigen measurements in high-risk prostate cancer families (Study VI) ................. 41 3. METHODS....................................................................................................................................................... 41 3.1. Estimation of standardized incidence ratios (Study I).......................................................................... 41 3.2. Cancer registry -based method for cancer family ascertainment (Study II)........................................ 42 3.3. Linkage analyses in Finnish prostate cancer families (Studies III and IV)........................................ 42 3.4. Association of E-Cadherin germline alterations with prostate and gastric cancers (Study V) ........... 44 3.5. Prostate spesific antigen measurements in high-risk prostate cancer families (Study VI) ................. 45 4. STATISTICAL METHODS (STUDIES I-VI).......................................................................................................... 45 5. ETHICAL CONSIDERATIONS............................................................................................................................. 45 
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2000
2000
Several predisposition loci for hereditary prostate cancer (HPC) have been suggested, including HPC1 at 1q24-q25 (OMIM #601518… (More)
  • table 1
  • table 2
Is this relevant?